Quality review, validation and availability of HPV tests <u>Commercially available HPV tests in 2020</u> <u>Mario Poljak, Marc Arbyn</u> <u>Faculty of Medicine, University of Ljubljana, Slovenia</u> <u>Scientific Institute of Public Health, Brussels, Belgium</u> Commercially available alpha-HPV molecular tests - periodical inventories -

2010

Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Exp Rev Anti Infect Ther 2010; 8: 1139-62,

2012

Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 2012; Suppl 30: F100-6.

2015

Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol 2016; 76: (Suppl 1): S3-S13.

2020

Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu, L, Arbyn M. Commercially available molecular tests for human papillomaviruses: a global overview. Clin Microbiol Infect 2020; 26: 1144-50.

2

 $\cdot\,$ not a simple addition of newly developed tests to the old list of HPV tests

• the existence of <u>all</u> HPV tests double-checked with manufacturers at every update round

• data retrieved from:

- Medline/Pubmed, Web of Science, Scopus, Bing, Google Scholar, Google without language or period restrictions - September 2019 and January 2020
- abstracts from main HPV-related conferences (2015-2020)
- internal files

- the Chinese National Medical Products Administration (formerly the China Food and Drug Administration) was consulted to obtain a list of HPV tests approved by agency

- conservative estimate very likely haven't identified all HPV tests currently available
- omission of any particular commercially available HPV test was unintentional

3

Test (distinct, unique) vs. test variant

particular HPV test was considered a variant if technologically identical or very similar to the original test but targeting different HPV type(s)

Human papillomavirus 16, 18 (DNA-Technology LLC, Moscow, Russia)	DISTINCT TEST
Human papillomavirus 18, 45, 39, 59	VARIANT
Human papillomavirus 16, 31, 33, 35, 58, 52, 67	VARIANT
Human papillomavirus 6, 11	VARIANT

4


254 distinct commercial HPV assays (and 425 variants) on the global market

	Tests	Variants
hr-HPV DNA screening tests	40	3
hr-HPV DNA screening tests with concurrent or reflex partial genotyping for the main hr-HPV types	41	3
HPV DNA full genotyping tests	91	21
HPV DNA type- or group-specific genotyping tests	38	89
hr-HPV E6/E7 mRNA tests	9	
in situ hybridization DNA in mRNA based HPV tests	33	308
HPV DNA tests targeting miscellaneous HPV types		
Total	254	425


ANT202A Mario Poljak



7



8



9




BUT

- <u>46</u>/254 (18.2%) of HPV tests with published performance evaluation (analytical and/or clinical)
 <u>56</u>/254 (22.1%) of HPV tests cross-sectional descriptive studies only no data for key test performance characteristics (sensitivity, specificity, reproducibility)
- "test A versus test B" approach with no reference standard
- ad hoc collections of heterogeneous clinical samples without follow-up
- various target population (including several non-genital)

Poljak M at al. Clin Microbiol Infect 2020; 26: 1144-50.

10

No.	DNA chip assay	Bioneer result	
1	16	16	
3	others	53	
2	54	54	
4	Others	33	
Negative sample	Negative	Negative	_



Main problems and limitations:

- manufacturers' webpages in local languages only
- lack of transparent webpages
- indirect marketing
- exclusive orientation towards the Western market
- situation on emerging markets poorly understood
- publication bias

13

Sample extraction part ?

- the majority of HPV tests currently on the market are not complete diagnostic assays: sample extraction part not included in the kit
- recommended nucleic acid extraction methodology not even mentioned in manufacturer's instructions
 only a minority of HPV tests on the market have internal controls
- the extraction of DNA/RNA is an invaluable part of the HPV testing procedure !

manufacturers should validate sample extraction procedure for each of the recommended sample collection devices and clinical sample types

list of validated sample collection devices and specimen types should be provided in the manufacturer's instructions

14

Issues to be resolved ...

we need complete HPV diagnostic assays including sample extraction procedure !

manufacturers should put more effort into evaluating their HPV products

- manufacturers should seek advice from established HPV researchers in the <u>very early phase of</u> <u>development</u> on:
- how to properly design a novel test
- define intended use of future test (clinical, epidemiological, research...)
- how to evaluate test performance that the HPV community will accept evaluation/validation results
- manufacturer-independent evaluations and publication of results in peer-reviewed journals are crucial

evaluation on alternative clinical specimens needed (self-collected cervicovaginal lavage specimens, vaginal swabs, other self-collected samples, tissues, urine...)

more competitively priced HPV tests needed !

15

COVID-19-related problems arising

- unprecedented health and economic impact of the COVID-19 pandemic
- extraordinary demand on a global scale for sampling devices, reagents, consumables, and diagnostic instruments needed for timely diagnosis of SARS-CoV-2 infection
- manufacturer's shift toward new niche market with unprecedented market growth opportunity
- serious COVID-19-related supply chain problems (reagents and consumables)
- shifted interest of public, agencies and medical journals ("nothing is important but COVID-19")
- temporary pause of cervical cancer screening programs
- "new normal"; unclear future; potential of second, third, fourth... waves of pandemic

16

Conclusions

- 254+ commercial HPV assays (and 425+ variants) on the global market
- 60% of HPV tests on the global market without a single peer-reviewed publication
- 81% of HPV tests on the market without published performance evaluation (analytical and/or clinical) in peer-reviewed journals
- great majority of performance evaluations not in line with standards agreed in the HPV community
- several clinically unvalidated HPV assays are used worldwide in daily practice only a small subset of HPV tests on the market has validated clinical performance
- serious COVID-19-related supply chain problems arising

only <u>clinically</u> validated HPV tests should be used in cervical cancer screening